DR. Reddy’s Laboratories Limited balance sheet RDY

Annual Quarterly

As of Mar 31, 2025, DR. Reddy’s Laboratories Limited had total assets of $5.8 billion and total liabilities of $1.8 billion. Total assets were up 24.1% from a year earlier. Stockholders' equity was $3.9 billion. It held $172.0 million in cash and investments against $547.0 million of total debt, net debt of $375.0 million. The current ratio, current assets divided by current liabilities, was 1.92.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Mar 31, 2022	FY 2021 Mar 31, 2021	FY 2020 Mar 31, 2020	FY 2019 Mar 31, 2019	FY 2018 Mar 31, 2018
Assets
Cash	172 +102.4%	85 +21.4%	70 -64.3%	196 -3.4%	203 +651.9%	27 -15.6%	32 -22.0%	41
Cash and investments	172 +102.4%	85 +21.4%	70 -64.3%	196 -3.4%	203 +651.9%	27 -15.6%	32 -22.0%	41
Receivables	1,058 +9.9%	963 +9.2%	882 +0.2%	880 +29.6%	679 +1.8%	667 +15.8%	576 -7.7%	624
Inventory	832 +9.0%	763 +28.9%	592 -11.8%	671 +8.1%	621 +33.5%	465 -4.3%	486 +8.7%	447
Total current assets	2,928 -1.6%	2,976 +18.2%	2,518 +5.0%	2,397 +18.3%	2,027 +17.2%	1,729 +4.4%	1,656 -1.7%	1,684
Property and equipment, net	1,144 +23.9%	923 +14.1%	809 -1.2%	819 +4.9%	781 +12.5%	694 -11.3%	782 -12.0%	889
Goodwill	138 +170.6%	51 -1.9%	52 -10.3%	58 -6.5%	62 +17.0%	53 -5.4%	56 -8.2%	61
Total assets	5,772 +24.1%	4,650 +18.7%	3,916 +1.5%	3,860 +6.3%	3,630 +17.8%	3,081 -5.5%	3,259 -5.9%	3,465
Liabilities and equity
Accounts payable	417 +12.4%	371 +15.2%	322 -4.5%	337 +3.7%	325 +47.1%	221 +5.2%	210 -15.0%	247
Total current liabilities	1,527 +32.6%	1,152 +10.3%	1,044 -15.7%	1,239 +8.7%	1,140 +18.0%	966 +11.9%	863 -19.3%	1,070
Total liabilities	1,825 +42.1%	1,284 +16.1%	1,106 -18.0%	1,348 +6.6%	1,264 +23.3%	1,025 -16.8%	1,232 -19.1%	1,523
Stockholders' equity	3,947 +17.3%	3,366 +19.8%	2,810 +11.9%	2,511 +6.1%	2,366 +15.1%	2,056 +1.4%	2,027 +4.4%	1,942
Debt
Debt due within a year	455 +169.2%	169 +14.2%	148 -60.0%	370 +12.8%	328 +19.3%	275 +16.0%	237 -39.5%	392
Long-term debt	92 +27.8%	72 +350.0%	16 -78.9%	76 -11.6%	86 +405.9%	17 -94.7%	318 -17.4%	385
Total debt	547 +127.0%	241 +47.0%	164 -63.2%	446 +7.7%	414 +41.8%	292 -47.4%	555 -28.6%	777
Net cash	-375 -140.4%	-156 -66.0%	-94 +62.4%	-250 -18.5%	-211 +20.4%	-265 +49.3%	-523 +28.9%	-736
Ratios
Current ratio	1.92x	2.58x	2.41x	1.93x	1.78x	1.79x	1.92x	1.57x
Debt to equity	0.14x	0.07x	0.06x	0.18x	0.17x	0.14x	0.27x	0.40x
Return on equity	17.00%	19.85%	19.50%	12.39%	9.97%	12.60%	13.42%	7.78%
Return on assets	11.63%	14.37%	13.99%	8.06%	6.50%	8.41%	8.35%	4.36%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: RDY (NYSE)
Fiscal year ends: March 31
Incorporated in: India
Headquarters: Hyderabad
SEC filer status: Large accelerated filer
SEC CIK: 1135951

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.